Publication | Closed Access
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer
138
Citations
25
References
2018
Year
Frontline Paclitaxel/carboplatin/bevacizumabMedicineGynecologyPhase Ii StudyAdvanced/recurrent Endometrial CancerCancer TreatmentOncologyRadiation OncologyGynecology OncologyMolecular OncologyEndocrine-related Cancer
| Year | Citations | |
|---|---|---|
2009 | 60.7K | |
2008 | 28.6K | |
2010 | 12.5K | |
1955 | 5.9K | |
2013 | 5.6K | |
2012 | 5.2K | |
2009 | 2.8K | |
2011 | 678 | |
2001 | 430 | |
2011 | 333 |
Page 1
Page 1